<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842267</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL019</org_study_id>
    <nct_id>NCT03842267</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of Gemigliptin 50mg in Patients With Type 2 Diabetes Who Have Inadequate glycemIc Control With Dapagliflozin and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg
      orally administered once daily for 24 weeks compared with placebo in patients with type 2
      diabetes mellitus who have inadequate glycemic control with dapagliflozin and metformin
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline HbA1c at week 24</measure>
    <time_frame>Baseline (week 0) and week 24</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Gemigliptin 50mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemigliptin Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin 50mg</intervention_name>
    <description>The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.
Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:
Dapagliflozin 10 mg / day
Metformin ≥ 1,000 mg / day</description>
    <arm_group_label>Gemigliptin 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin Placebo</intervention_name>
    <description>The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.
- The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.
Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:
Dapagliflozin 10 mg / day
Metformin ≥ 1,000 mg / day</description>
    <arm_group_label>Gemigliptin Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with type 2 diabetes mellitus of upper 19 years old at the time of Visit 1
             (Screening)

          2. Visit 1 (Screening) Patients who had taken Dapagliflozin 10mg/day and
             Metformin(≥1000mg/day) more than 8 weeks and who have inadequate blood glucose control
             at Visit 1 (Screening)

          3. Patients who have signed an informed consent themselves after receiving explanation
             about the objectives, methods, effects, etc. of the clinical study

          4. Patients who are applicable to one of the three in the following. 1) Surgically
             infertile patients 2) Postmenopausal female patients of ≥45 years of age for whom ≥2
             years elapsed since their last menstruation 3) Premenopausal fertile female patients
             or surgically non-infertile male patients who have agreed to use at least 2 kinds of
             contraceptive measures (certainly including one of the barrier methods) to avoid
             pregnancy until 14 days after the last dose of the investigational product

               -  Barrier methods: Condom, Diaphragm, Cervical cap(Pessary), Spermicide

               -  Hormonal methods: Pills, Injection(Depot), Skin patch, Hormonal
                  implant(Implanon), Vaginal ring

               -  Intrauterine Devices(IUDs): Cooper IUD(Loop), Hormonal IUD(Mirena)

               -  Natural methods: Basic body temperature, Ovulation period, Coitus interruptus,
                  Abstinence

        Exclusion Criteria:

          1. Patients with type 1 diabetes mellitus, Diabetic ketoacidosis, Metabolic acidosis
             Diabetic coma, Diabetic pre-coma

          2. Patients with Gestational diabetes, or secondary diabetes

          3. Patients with Body Mass Index(BMI) ＞40 kg/m2 at the time of Visit 1(Screening)

          4. Patients with a history of the following

               -  Patients with NYHA Class II~IV congestive heart failure or arrhythmia requiring
                  treatment at the time of Visit 1(Screening)

               -  Patients whose TSH level is out of the normal range and who have thyroidal
                  dysfunction requiring drug therapy at the time of Visit 1(Screening) (However,
                  those who have been taking thyroid hormone at a fixed dose since previous 4 weeks
                  prior to Visit 1(Screening) and whose TSH level is within the normal range can
                  participate in the study.)

               -  Patients with a glomerular filtration rate (eGFR) less than 60 mL/min /1.73 m2,
                  moderate of severe stage renal disease, end-stage renal disease, dialysis at the
                  time of Visit 1(Screening)

               -  Patients who are receiving intravenous iodine contrast agents within 48 hours
                  prior to Visit 1(Screening) or planned during the clinical trial period (eg,
                  intravenous urography, venous cholangiography, angiography, computed tomography
                  using contrast media, etc.).

               -  Patients with pulmonary embolism, severe pulmonary dysfunction, or who are
                  susceptible to be accompanied by hypoxemia at the time of Visit 1(Screening)

               -  Patients on dehydration, diarrhea, and vomiting at the time of Visit 1(Screening)

               -  Patients with pituitary insufficiency or adrenal insufficiency at the time of
                  Visit 1(Screening)

               -  Patients with a history of myocardial infarction, unstable angina, and
                  Cerebrovascular disease within 12 weeks prior to Visit 1(Screening)

               -  Patients who had had a surgical operation within 4 weeks prior to Visit
                  1(Screening) (excluding minor surgeries without restriction on food and fluid
                  intake) or who are scheduled to have a significant surgery during the study
                  period

               -  Patients with a history of alcoholism or drug addiction within 1 years prior to
                  Visit 1(Screening)

               -  Patients with a history of malignant tumors within 5 years prior to Visit
                  1(Screening). However, patients with basal cell or squamous cell skin cancer, or
                  in situ cervical cancer treated properly can participate in the study.

          5. Patients with the outcomes of the laboratory tests performed at Visit 1(Screening)
             applicable to the criteria below

               -  Bilirubin &gt;2 × upper limit of normal(ULN)

               -  AST/ALT &gt;3 × ULN

          6. Patients with a history of hypersensitivity reactions to the drugs below

               -  Dipeptidyl-peptidase4(DPP4) inhibitors

               -  Sodium/glucose co transport-2(SGLT-2) inhibitor

               -  Biguanides

          7. Patients who were administered the drugs below

               -  Patients who had been administered anti-obesity drugs within 12 weeks prior to
                  Visit 1(Screening)

               -  Patients who had been administered insulin or GLP-1 analogues within 8 weeks
                  prior to Visit 1(Screening)

               -  Patients who had been being administered glucocorticoids, Strong CYP3A4 inducers
                  continuously within 2 weeks prior to Visit 1(Screening) or who are required to
                  take glucocorticoids continuously in the future

          8. Patients with positive Serologic results of HBsAg, HCV Ab, HIV Ab test within 4 weeks
             prior to Visit 1 (Screening) or at Visit 1 (Screening)

          9. Patients who have undergone bariatric surgery within the 1 year prior to Visit 1
             (Screening) or are scheduled during the trial

         10. Patients with a genetic problems such as Galactose intolerance, Lapp lactose
             deficiency, Glucose-galactose malabsorption)

         11. Female patients who are pregnant or lactating

         12. Patients who have an experience of participation in another clinical study within 12
             weeks prior to Visit1(screening)

         13. Patients who are otherwise considered to be ineligible for this study on
             investigators' judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Subin Lee</last_name>
    <phone>+82-6987-4157</phone>
    <phone_ext>+82-6987-4157</phone_ext>
    <email>leesubin@lgchem.com</email>
  </overall_contact>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

